{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:09:52Z","timestamp":1791328192960,"version":"4.3.1"},"reference-count":95,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ketamine and esketamine have demonstrated rapid, short-term antidepressant effects in major depressive disorder (MDD), but their relative safety remains unclear. This review aims to update the evidence on the safety of two agents for MDD and indirectly compare their safety and tolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We systematically searched PubMed, PsycINFO, Embase, and Cochrane databases up to 1 May 2025. Eligible studies compared ketamine or esketamine with placebo, active psychotropic agents, or electroconvulsive therapy in adults with MDD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We retrieved 5,473 articles, 47 of which met the inclusion criteria. For ketamine versus placebo, both dropout and incidence rates of adverse events (AEs) were statistically significant, with number needed to harm (NNH) values of 12 and 2, respectively. A similar pattern of effect sizes was found for esketamine, but with higher corresponding NNH values. Conversely, neither the meta-analysis nor NNH analyses of the incidence of serious AEs for ketamine and esketamine were statistically significant. A series of AEs like dizziness, dissociation, nausea, vertigo, and vision blurred, with relatively low NNH values, would be more likely to occur in clinical practice and exhibit dose-dependent effects. Moreover, ketamine or esketamine was associated with transient and significant psychiatric side-effects, blood pressure increases, and sedation post-dose. No significant abnormalities were observed in cognitive impairments, laboratory results, bladder symptoms, nasal examination, or addiction-related evaluations for either drug.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although further promising evidence supports the safety of ketamine and esketamine for MDD, the findings of this study highlight a potential tolerability advantage with esketamine over ketamine for short-term use for MDD. These findings require further validation through direct head-to-head clinical trials comparing these two drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42023389486<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1681060","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:07:46Z","timestamp":1761721666000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Comparative safety and tolerability of ketamine and esketamine for major depressive disorder: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Haoning","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liling","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaoquan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencheng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuying","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jisheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueli","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","article-title":"Diagnostic and statistical manual of mental disorders","year":"2024","DOI":"10.1176\/appi.books.9780890425596"},{"key":"B2","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jad.2018.02.056","article-title":"Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial","volume":"235","author":"Arabzadeh","year":"2018","journal-title":"J. Affect. Disord."},{"key":"B3","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jad.2020.09.071","article-title":"Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis","volume":"278","author":"Bahji","year":"2021","journal-title":"J. Affect. Disord."},{"key":"B4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/s0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatry."},{"key":"B5","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jad.2024.04.039","article-title":"Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: a systematic review and meta-analysis","volume":"356","author":"Calder","year":"2024","journal-title":"J. Affect. Disord."},{"key":"B6","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1176\/appi.ajp.2018.17060720","article-title":"Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study","volume":"175","author":"Canuso","year":"2018","journal-title":"Am. J. Psychiatry."},{"key":"B7","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40263-021-00846-5","article-title":"Prevention and management of common adverse effects of ketamine and esketamine in patients with mood disorders","volume":"35","author":"Ceban","year":"2021","journal-title":"CNS. Drugs."},{"key":"B8","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2147\/NDT.S391096","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray plus a newly initiated oral antidepressant in adult patients with treatment-resistant depression: a randomized, double-blind, multicenter, active-controlled study conducted in China and USA","volume":"19","author":"Chen","year":"2023","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"B9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jad.2020.03.106","article-title":"Appraising esketamine nasal spray for the management of treatment-resistant depression in adults: number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"271","author":"Citrome","year":"2020","journal-title":"J. Affect. Disord."},{"key":"B10","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jpsychires.2024.03.002","article-title":"Oral prolonged-release ketamine in treatment-resistant depression - a double-blind randomized placebo-controlled multicentre trial of KET01, a novel ketamine formulation \u2013 clinical and safety results","volume":"173","author":"Colla","year":"2024","journal-title":"J. Psychiatr. Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e12414","DOI":"10.1097\/MD.0000000000012414","article-title":"Comparative study of esketamine and racemic ketamine in treatment-resistant depression: protocol for a non-inferiority clinical trial","volume":"97","author":"Correia-Melo","year":"2018","journal-title":"Med. Baltim."},{"key":"B13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","article-title":"Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial","volume":"75","author":"Daly","year":"2018","journal-title":"JAMA. Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial","volume":"76","author":"Daly","year":"2019","journal-title":"JAMA. Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"Cd011612","DOI":"10.1002\/14651858.CD011612.pub3","article-title":"Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder","volume":"9","author":"Dean","year":"2021","journal-title":"Cochrane. Database. Syst. Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40263-020-00699-4","article-title":"Cardiac safety of esketamine nasal spray in treatment-resistant depression: results from the clinical development program","volume":"34","author":"Doherty","year":"2020","journal-title":"CNS Drugs"},{"key":"B17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1192\/bjp.2018.196","article-title":"Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"214","author":"Domany","year":"2019","journal-title":"Br. J. Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.euroneuro.2016.03.006","article-title":"Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate","volume":"26","author":"Downey","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/ijnp\/pyab088","article-title":"Racemic ketamine as an alternative to electroconvulsive therapy for unipolar depression: a randomized, open-label, non-inferiority trial (KetECT)","volume":"25","author":"Ekstrand","year":"2022","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41380-018-0256-5","article-title":"Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)","volume":"25","author":"Fava","year":"2020","journal-title":"Mol. Psychiatry."},{"key":"B21","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1)","volume":"22","author":"Fedgchin","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e080409","DOI":"10.1136\/bmj-2024-080409","article-title":"Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study","volume":"387","author":"Feldman","year":"2024","journal-title":"Bmj"},{"key":"B23","doi-asserted-by":"publisher","first-page":"19m13191","DOI":"10.4088\/JCP.19m13191","article-title":"Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I)","volume":"81","author":"Fu","year":"2020","journal-title":"J. Clin. Psychiatry."},{"key":"B95","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1177\/0269881118760660","article-title":"Repeated intranasal ketamine for treatment-resistant depression - the way to go? Results from a pilot randomised controlled trial","volume":"32","author":"G\u00e1lvez","year":"2018","journal-title":"J Psychopharmacol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000510703","article-title":"Post-Marketing safety concerns with esketamine: a disproportionality analysis of spontaneous reports submitted to the FDA adverse event reporting system","volume":"90","author":"Gastaldon","year":"2021","journal-title":"Psychother. Psychosom."},{"key":"B92","first-page":"492","article-title":"Severe asymptomatic hypertension: evaluation and treatment","volume":"95","author":"Gauer","year":"2017","journal-title":"Am. Fam. Physician."},{"key":"B91","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.drudis.2016.01.016","article-title":"Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity","volume":"21","author":"Gerhard","year":"2016","journal-title":"Drug Discov. Today."},{"key":"B94","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.psychres.2013.12.008","article-title":"Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder","volume":"215","author":"Ghasemi","year":"2014","journal-title":"Psychiatry Res."},{"key":"B96","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.neubiorev.2020.11.020","article-title":"The effects of ketamine on cognition in treatment-resistant depression: a systematic review and priority avenues for future research","volume":"120","author":"Gill","year":"2021","journal-title":"Neurosci Biobehav. Rev."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1038\/s41591-024-03063-x","article-title":"Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial","volume":"30","author":"Glue","year":"2024","journal-title":"Nat. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1176\/appi.ajp.2017.17060647","article-title":"Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial","volume":"175","author":"Grunebaum","year":"2018","journal-title":"Am. J. Psychiatry."},{"key":"B26","doi-asserted-by":"publisher","first-page":"849758","DOI":"10.3389\/fphar.2022.849758","article-title":"Neurological adverse events associated with esketamine: a disproportionality analysis for signal detection leveraging the FDA adverse event reporting system","volume":"13","author":"Guo","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B27","unstructured":"Cochrane handbook for systematic reviews of interventions version 6.5\n          \n          \n            \n              Higgins\n              J. P.\n            \n            \n              Thomas\n              J.\n            \n            \n              Chandler\n              J.\n            \n            \n              Cumpston\n              M.\n            \n            \n              Li\n              T.\n            \n            \n              Page\n              M. J.\n            \n          \n          \n          2024"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2025.04.077","article-title":"Efficacy and safety of esketamine for smoking cessation among patients diagnosed with lung cancer and major depression disorder: a randomized, placebo-controlled clinical trial","volume":"383","author":"Hong","year":"2025","journal-title":"J. Affect Disord."},{"key":"B29","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1017\/s0033291715002159","article-title":"Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study","volume":"46","author":"Hu","year":"2016","journal-title":"Psychol. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jad.2018.09.037","article-title":"Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: a randomized, double blind, placebo controlled trial","volume":"243","author":"Ionescu","year":"2019","journal-title":"J. Affect. Disord."},{"key":"B31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/ijnp\/pyaa068","article-title":"Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a phase 3, double-blind, randomized study (ASPIRE II)","volume":"24","author":"Ionescu","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B32","unstructured":"Spravato\u00ae esketamine nasal spray, product monography including patient medication information\n          \n          \n            \n              Janssen\n              I.\n            \n          \n          \n          2020"},{"key":"B33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1503\/jpn.120065","article-title":"Publication bias: what are the challenges and can they be overcome?","volume":"37","author":"Joober","year":"2012","journal-title":"J. Psychiatry. Neurosci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1177\/0004867413486842","article-title":"Ketamine as a new treatment for depression: a review of its efficacy and adverse effects","volume":"47","author":"Katalinic","year":"2013","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","first-page":"21m13921","DOI":"10.4088\/JCP.21m13921","article-title":"Effects of ketamine versus midazolam on neurocognition at 24 hours in depressed patients with suicidal ideation","volume":"82","author":"Keilp","year":"2021","journal-title":"J. Clin. Psychiatry"},{"key":"B36","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/jcp.0000000000001289","article-title":"Comparison of rapid antidepressant and antisuicidal effects of intramuscular ketamine, oral ketamine, and electroconvulsive therapy in patients with major depressive disorder: a pilot study","volume":"40","author":"Kheirabadi","year":"2020","journal-title":"J. Clin. Psychopharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1017\/s0033291716000064","article-title":"Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories","volume":"46","author":"Kishimoto","year":"2016","journal-title":"Psychol. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.biopsych.2014.03.026","article-title":"A randomized controlled trial of intranasal ketamine in major depressive disorder","volume":"76","author":"Lapidus","year":"2014","journal-title":"Biol. Psychiatry."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/hbm.23085","article-title":"The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: a randomized controlled study","volume":"37","author":"Li","year":"2016","journal-title":"Hum. Brain. Mapp."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41386-021-01242-9","article-title":"Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial","volume":"47","author":"Lijffijt","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jad.2012.04.032","article-title":"Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial","volume":"142","author":"Loo","year":"2012","journal-title":"J. Affect. Disord."},{"key":"B42","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1192\/bjp.2023.79","article-title":"Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial","volume":"223","author":"Loo","year":"2023","journal-title":"Br. J. Psychiatry"},{"key":"B43","doi-asserted-by":"publisher","first-page":"109378","DOI":"10.1016\/j.neuropharm.2022.109378","article-title":"NMDA receptors as therapeutic targets for depression treatment: evidence from clinical to basic research","volume":"225","author":"Lv","year":"2023","journal-title":"Neuropharmacology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/eb-2015-102299","article-title":"Is treatment-resistant depression a useful concept?","volume":"19","author":"Malhi","year":"2016","journal-title":"Evid. Based Ment. Health"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1011103","DOI":"10.3389\/fnins.2022.1011103","article-title":"The effect of ketamine on cognition, anxiety, and social functioning in adults with psychiatric disorders: a systematic review and meta-analysis","volume":"16","author":"Marchi","year":"2022","journal-title":"Front. Neurosci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jad.2024.02.052","article-title":"Cognitive outcomes from the randomised, active-controlled ketamine for adult depression study (KADS)","volume":"352","author":"Martin","year":"2024","journal-title":"J. Affect. Disord."},{"key":"B47","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am. J. Psychiatry."},{"key":"B48","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s40263-018-0519-3","article-title":"Antidepressant efficacy and tolerability of ketamine and esketamine: a critical review","volume":"32","author":"Molero","year":"2018","journal-title":"CNS. Drugs."},{"key":"B93","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1360-0443.2011.03576.x","article-title":"Independent scientific committee on drugs","volume":"107","author":"Morgan","year":"2012","journal-title":"Ketamine use: a review"},{"key":"B49","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/sj.npp.1300342","article-title":"Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers","volume":"29","author":"Morgan","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1360-0443.2009.02761.x","article-title":"Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study","volume":"105","author":"Morgan","year":"2010","journal-title":"Addiction"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial","volume":"170","author":"Murrough","year":"2013","journal-title":"Am. J. Psychiatry."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/npp.2014.298","article-title":"Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial","volume":"40","author":"Murrough","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jagp.2019.10.008","article-title":"Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3","volume":"28","author":"Ochs-Ross","year":"2020","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"B54","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/pcn.13734","article-title":"Efficacy and safety of intravenous ketamine treatment in Japanese patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial","volume":"78","author":"Ohtani","year":"2024","journal-title":"Psychiatry Clin. Neurosci."},{"key":"B55","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jclinepi.2021.03.001","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"134","author":"Page","year":"2021","journal-title":"J. Clin. Epidemiol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1186\/s12888-024-05951-5","article-title":"A randomized controlled pilot study of daily intravenous ketamine over three days for treatment-resistant depression","volume":"24","author":"Pattanaseri","year":"2024","journal-title":"BMC Psychiatry"},{"key":"B57","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am. J. Psychiatry."},{"key":"B58","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/da.22253","article-title":"Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression","volume":"31","author":"Price","year":"2014","journal-title":"Depress. Anxiety."},{"key":"B59","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1001\/archpsyc.1984.01790190056007","article-title":"Identification of true drug response to antidepressants. Use of pattern analysis","volume":"41","author":"Quitkin","year":"1984","journal-title":"Arch. Gen. Psychiatry"},{"key":"B60","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1001\/archpsyc.1987.01800150071009","article-title":"Use of pattern analysis to identify true drug response. A replication","volume":"44","author":"Quitkin","year":"1987","journal-title":"Arch. Gen. Psychiatry"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1176\/appi.ajp.162.6.1171","article-title":"Quality-of-life impairment in depressive and anxiety disorders","volume":"162","author":"Rapaport","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1056\/NEJMoa2304145","article-title":"Esketamine nasal spray versus quetiapine for treatment-resistant depression","volume":"389","author":"Reif","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1001\/jamapsychiatry.2022.3352","article-title":"Efficacy and safety of ketamine vs electroconvulsive therapy among patients with major depressive episode: a systematic review and meta-analysis","volume":"79","author":"Rhee","year":"2022","journal-title":"JAMA. Psychiatry."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1080\/14740338.2020.1776699","article-title":"Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence","volume":"19","author":"Rodrigues","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"B65","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.psychres.2016.04.117","article-title":"Peripheral oxytocin and vasopressin: biomarkers of psychiatric disorders? A comprehensive systematic review and preliminary meta-analysis","volume":"241","author":"Rutigliano","year":"2016","journal-title":"Psychiatry. Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"104413","DOI":"10.1016\/j.ajp.2025.104413","article-title":"Oral ketamine for rapid reduction of suicidal ideation in major depressive disorder: a midazolam-controlled randomized clinical trial","volume":"106","author":"Seraj","year":"2025","journal-title":"Asian J. Psychiatry"},{"key":"B67","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41398-020-00897-0","article-title":"A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression","volume":"10","author":"Shiroma","year":"2020","journal-title":"Transl. Psychiatry."},{"key":"B68","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/s2215-0366(17)30272-9","article-title":"Side-effects associated with ketamine use in depression: a systematic review","volume":"5","author":"Short","year":"2018","journal-title":"Lancet. Psychiatry"},{"key":"B69","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.biopsych.2015.10.018","article-title":"Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study","volume":"80","author":"Singh","year":"","journal-title":"Biol. Psychiatry."},{"key":"B70","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1176\/appi.ajp.2016.16010037","article-title":"A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression","volume":"173","author":"Singh","year":"","journal-title":"Am. J. Psychiatry."},{"key":"B71","doi-asserted-by":"publisher","first-page":"22m14548","DOI":"10.4088\/JCP.22m14548","article-title":"Comparative effectiveness of intravenous ketamine and intranasal esketamine in clinical practice among patients with treatment-refractory depression: an observational study","volume":"84","author":"Singh","year":"2023","journal-title":"J. Clin. Psychiatry"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1038\/s41380-024-02478-9","article-title":"Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension","volume":"29","author":"Smith-Apeldoorn","year":"2024","journal-title":"Mol. Psychiatry"},{"key":"B73","first-page":"287","article-title":"Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression","volume":"34","author":"Sos","year":"2013","journal-title":"Neuro. Endocrinol. Lett."},{"key":"B74","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1146\/annurev-publhealth-061022-040533","article-title":"The economics of treatment for depression","volume":"45","author":"Stecher","year":"2024","journal-title":"Annu. Rev. Public Health"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/npp.2017.94","article-title":"Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression","volume":"42","author":"Su","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"B76","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/ijnp\/pyad014","article-title":"A randomized, double-blind, midazolam-controlled trial of low-dose ketamine infusion in patients with treatment-resistant depression and prominent suicidal ideation","volume":"26","author":"Su","year":"2023","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B77","first-page":"585","article-title":"Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety","volume":"31","author":"Szarmach","year":"2019","journal-title":"Psychiatr. Danub"},{"key":"B78","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1186\/s12888-021-03538-y","article-title":"Efficacy and safety of fixed doses of intranasal esketamine as an add-on therapy to oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study","volume":"21","author":"Takahashi","year":"2021","journal-title":"Bmc. Psychiatry"},{"key":"B79","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41398-020-0844-4","article-title":"A randomized placebo-controlled PET study of ketamine\u00b4s effect on serotonin(1B) receptor binding in patients with SSRI-Resistant depression","volume":"10","author":"Tiger","year":"2020","journal-title":"Transl. Psychiatry."},{"key":"B80","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/npp.2011.306","article-title":"Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review","volume":"37","author":"Undurraga","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"B81","unstructured":"Full prescribing information of ketamine\n          \n          \n          2022"},{"key":"B82","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1007\/s00213-017-4706-6","article-title":"The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study","volume":"234","author":"van de Loo","year":"2017","journal-title":"Psychopharmacol. Berl."},{"key":"B83","doi-asserted-by":"publisher","first-page":"549080","DOI":"10.3389\/fpsyt.2021.549080","article-title":"Meta-analysis: hemodynamic responses to sub-anesthetic doses of ketamine in patients with psychiatric disorders","volume":"12","author":"Vankawala","year":"2021","journal-title":"Front. Psychiatry."},{"key":"B84","unstructured":"Depression fact sheet\n          \n          \n          2016"},{"key":"B85","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.drudis.2018.11.007","article-title":"A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate\/GABA neurotransmitter systems","volume":"24","author":"Wilkinson","year":"2019","journal-title":"Drug. Discov. Today"},{"key":"B86","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.jad.2024.01.142","article-title":"A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): a systematic review","volume":"350","author":"Wong","year":"2024","journal-title":"J. Affect. Disord."},{"key":"B87","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41398-019-0624-1","article-title":"Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites","volume":"9","author":"Yang","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"B88","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"B89","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s12888-024-05716-0","article-title":"Rapid and sustained antidepressant effects of intravenous ketamine in treatment-resistant major depressive disorder and suicidal ideation: a randomized clinical trial","volume":"24","author":"Zolghadriha","year":"2024","journal-title":"BMC Psychiatry"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1681060\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:07:49Z","timestamp":1761721669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1681060\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":95,"alternative-id":["10.3389\/fphar.2025.1681060"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1681060","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"article-number":"1681060"}}